Infliximab

Infliximab
Measuring Infliximab drug concentrations in patients being treated with Infliximab for chronic autoimmune and inflammatory conditions

Therapeutic Drug Monitoring (TDM) is to optimize biologic treatment for an individual patient. AFIAS Infliximab allows for reliable measurement of Infliximab drug levels using just a small amount of human serum, plasma, or whole blood, delivering results in 10 minutes. This allows clinicians to confirm the drug levels of Infliximab immediately before the next administration.

About Using Reagent

• Sample Types plasma, serum, and whole blood
• Reaction Time 10 mins
  
• Detection Range 0.2~50 μg/mL
  
• Indication Quantitative determination of free infliximab in human whole blood/serum/plasma
  

Click